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Abstract Pessaries have been used to treat women with
pelvic organ prolapse (POP) since the beginning of
recorded history. This review aims to assess the effect of
pessary treatment on the disease-specific, health-related
quality of life in women with pelvic organ prolapse. After a
Medline search using the Mesh term ‘pessary’ and critical
appraisal, 41 articles were selected and used in this review.
Pessaries are widely used to treat pelvic organ prolapse. It
is minimally invasive and appears to be safe. Although
there is evidence that the use of pessaries in the treatment of
pelvic organ prolapse is effective in alleviating symptoms
and that patient satisfaction is high, the follow-up in many
published papers is short, and the use of validated
urogynaecological questionnaires is limited. Comparison
with surgical treatment of pelvic organ prolapse is rare and
not assessed in a randomised controlled trial.
Keywords Pelvic organ prolapse.Pessaries.Pessary.
Quality of life.Surgery.Urogenital
Introduction
Pessaries have been used to treat women with pelvic organ
prolapse since the beginning of recorded history. Hippocrates
described reduction of vaginal prolapse by placing a halved
pomegranate soaked in wine into the vagina (Fig. 1)[ 1].
A variety of devices has been described over time [2].
Nowadays, most pessaries are made of silicone and are ring
type pessaries with or without central support, Gellhorn
pessaries and donut pessaries (Fig. 2)[ 3]. Pessaries are used
in daily practice by more than 86% of gynaecologists and
98% of urogynaecologists [4, 5]. The ring with central
support and the Gellhorn pessary are most frequently used
and appear equally effective in relieving symptoms of
genital prolapse and voiding dysfunction [6].
It is not clear which patients particularly benefit most
from pessary treatment, what the side effects are and
whether the therapeutic effect is high enough to condone
possible side effects. Most important is whether pessary
treatment reduces urogenital bother symptoms and which
impact it has on health-related quality of life [7]. In the end,
it is not the doctor’s but the patient’s opinion about the
treatment that is most important. Health-related quality of
life is one of the patient outcome measures (POM) and is
measured and quantified in domain scores of validated
urogynaecological questionnaires. The use of these validated
questionnaires to assess health-related quality of life in
surgery of pelvic organ prolapse (POP) is well established.
Althoughpessarytreatmentiswidelyusedforthetreatmentof
pelvic organ prolapse as well, a (systematic) review on the
quality of life following pessary treatment has not yet been
published.
This review aims to assess the effects of pessary
treatment on disease-specific health-related quality of life
in women with POP.
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We searched Medline (1966 to December 2010) using the
Mesh term ‘pessary’ and limits ‘female’ AND ‘human’.
This resulted in 726 articles. An additional search on
Embase using the term ‘pessary’ and limits ‘human’
resulted in 633 articles. After screening of both title and
abstract, we were left with 159 articles related to pelvic
organ prolapse and pessary. This review focused solely on
pessary treatment in pelvic organ prolapse. Therefore,
articles regarding pessary treatment in urinary incontinence
or other conditions were excluded. Guidelines on how to fit
a pessary, case reports describing rare complications
without any literature review and experts’ letters were
excluded. From the remaining 41 articles which were
considered useful, 13 articles were a review [2, 5, 8–18],
and 28 articles were original research articles [3, 4, 6, 7,
19–43]. Only 10 articles [6, 19–21, 25, 27, 32, 34, 35, 41]
met the exact criteria of the reviewers’ aim to assess the
health-related quality of life in women with pelvic organ
prolapse. Although the other articles did not meet these pre-
specified criteria, they were considered useful in additional
analyses, such as for example which women are most
suitable for pessary treatment, successful fitting, dropout
rates and management of pessary treatment. Table 1 shows
a description of papers included in this review. This review
was originally set up as a systematic review. After reviewing
the articles, there was inconsistency in definitions such as
successful fitting and dropout rates, sample sizes, and
follow-up periods, and there was shortage of studies that
met the exact criteria. Therefore, the goal of a systematic
review could unfortunately not be achieved, but the
available (or lack of) research articles did, to our opinion,
justify the present review.
Patient suitability
Which patients are considered suitable for pessary treatment
remains unclear from the literature. Patients themselves may
have preconceived ideas, and both beliefs and attitudes
regarding the aetiology and success of pessary treatment
may influence their choice of treatment [3, 22, 31, 33].
Some factors contributing to patient’s choices appear to be
independently associated with treatment choices of patients in
a fairly predictable way. The probability of choosing pessary
treatment over surgery increases as patients’ age rises and
respectivelydecreases asstage ofPOPincreases [31]. Women
who already have undergone prior POP surgery are more
eager to choose POP surgery again [31]. Women preferring
surgery to pessary treatment for POP reported more
bothersome symptoms related to POP and felt more affected
by POP in their general well-being [33]. Furthermore, the
majority of patients who were sexually active tended to
prefer surgery above conservative treatment [33].
Failure of fitting and continuation of pessary use
Most papers reported that there are certain groups of
patients that drop out. There are patients who initially do
Fig. 2 Pessary most prescribed. Donut, Gellhorn, ring with and
without support (Milex Products, Inc.)
Fig. 1 Reduction of vaginal prolapse by placing a halved pomegranate
soaked in wine into the vagina described by Hippocrates
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There is an additional group of patients who abandon
pessary treatment after some weeks because of discom-
fort or repeated expulsions [30]. There is no agreement in
the literature on what is considered successful pessary
fitting. Some authors considered fitting successful if a
pessary was perceived comfortable by a patient when
retained during Valsalva and voiding, at the initial patient
visit, while others considered fitting successful if a patient
continued to use the pessary until the following doctor’s
appointment [40]. Therefore, the rate of unsuccessful
fitting and dropout ranges widely. Table 2 offers an
overview of successful fitting and dropout rates of studies
included in this review. In this review, we considered
fitting to be successful if a patient comfortably retained a
pessary at their first visit. A patient was considered to drop
out if they abandoned pessary use at the following doctors’
appointment.
Most studies reported successful fitting rates to be over
85%. Risk factors that are reported to be responsible for
unsuccessful pessary fitting are short vaginal length, a large
genital hiatus, prior history of hysterectomy and prior
surgical repairs of POP [37, 39].
The compartment and stage of POP have not been
reported to have any influence on successful pessary
fitting and should therefore not be a factor of patient
selection for pessary treatment [39]. Continuation rates
on the short-term range from 50% to 80% after 3 or
4 months. After 1 year of use, the continuation rates
remain unchanged: 50–80%. Only two studies reported
long-term continuation of pessary use over more than
1 year. One study reported a continued pessary use in
48% of patients for an average duration of 5.4 years
[23]. A more recent study on the long term reported a
14% continued pessary use with a mean duration of
7 years [43].
An independent factor associated with the continued use
of a pessary is age above 65 years. Sexually active women
were more likely to continue wearing a pessary for a longer
period of time [22, 26, 28].
Improvement in POP-related bother and health-related
quality of life
POP causes symptoms that have impact on patients’
daily activities and quality of life. Women with POP
seem to have a negative body image compared to women
without POP [44]. Women who seek medical advice
perceive these symptoms bothersome enough to opt for
treatment and strive to improve their perceived quality of
life [44].
We found only few articles in which validated urogy-
naecological questionnaires were used to asses treatment
effects on health-related quality of life [6, 19, 21, 27, 32,
34, 35, 41]. Two articles did not use validated question-
naires but measured improvement of POP symptoms and
satisfaction in pessary users with questionnaires that
Table 1 Description of papers used in the review
Description of research Number of articles, n=41 References
Quality of life changes in pessary use in pelvic organ prolapse 10 [4, 6, 19–21, 25, 27, 32, 34, 35]
Successful fitting pessary and dropout rates in pelvic organ prolapse 20 [6, 19–25, 27, 28, 30, 32, 34, 35, 37, 39–43]
Continuation rate long-term pessary use 3 [23, 27, 43]
Patients suitability 6 [3, 14, 20, 22, 31, 33]
Anatomical changes after pessary use 3 [29, 32, 38]
Complication and discomfort 6 [1, 9, 18, 23, 27, 43]
Management of pessary treatment 11 [1, 3, 5, 10, 14–18, 21, 30]
Research design
Review 13 [2, 5, 8–18]
Retrospective study 10 [3, 20, 22, 23, 28, 30, 37, 39, 42, 43]
Prospective study 13 [7, 19, 21, 24–27, 29, 33–36, 41]
Randomised and quasi-randomised trials 3 [4, 6, 40]
Cross-sectional 1 [31]
Observational cohort 1 [32]
Case report 1 [38]
Int Urogynecol J (2011) 22:637–644 639were not validated [20, 25]. Other questionnaires that
were used were the Female Sexual Function Index
Questionnaire (FSFI), the Pelvic Floor Distress Inventory
(PFDI), the Pelvic Floor Impact Questionnaire (PFIQ),
the Body Image Scale, the Sheffield Pelvic Organ
Prolapse Symptom Questionnaire and the King’sH e a l t h
Questionnaire. The PFDI and PFIQ have been validated
for use in women with POP [41]. The body image scale
evaluates a woman’s self-perception of her physical
appearance, attractiveness, and satisfaction with her
body. This questionnaire has been used in research on
women with cancer and was considered valid and
reliable for that group of patients, but is not yet validated
for use in women with POP [45]. The FSFI is a validated
questionnaire that refers to the domains of desire, arousal,
lubrication, orgasm and satisfaction in sexual functioning
[46]. The Sheffield prolapse questionnaire relates to the
severity of POP specific symptoms, while the King’s
Health Questionnaire evaluates domains of health-related
quality of life [35]. The results of 10 available studies are
shown in Table 3. Consistent in most papers is the
improvement gained in both bulge and irritative bladder
symptoms following pessary treatment. Two studies
reported de novo stress urinary incontinence [25, 35].
Women who were sexually active and wore a pessary
reported a significant increase in both frequency and
satisfaction of sexual activity [19, 27]. There were
significant improvements in desire, lubrification and
sexual satisfaction after treatment of POP with a pessary
[35]. These findings may have resulted of improvements
in general well-being which may have altered patients’
self-esteem. These data are suggestive that a vaginal
pessary does not negatively interfere with sexual activity
and may even improve sexual functioning as a whole.
Patients’ satisfaction rates with medium-term pessary use
are high (70–92%) [20, 25]. Pessary treatment for 3 months
not only reduced POP-related bother symptoms but also
caused improvement in quality of life and women’s
perception of their body image [41].
A recently published study compared the effectiveness of
pessaries with surgery in women with symptomatic POP [19].
The authors reported similar improvements in urinary, bowel,
sexual function and quality of life parameters in both
treatment arms. That suggests that pessary treatment in POP
might be as effective as surgery in improving health-related
quality of life.
Table 2 Successful fitting and dropout rates
Author publication year
[reference]
Number Study design Initially successful
fitting, n (%)
a
Dropout at follow-up,
n (%)
b
Follow-up
in months
Clemons 2004 [24] 100 Prospective 94 (94) 21 (22) 0.5
Brincat 2004 [22] 136 Retrospective Unknown 54 (40) 4
Clemons 2004 [26] 59 Prospective Unknown 16 (27) 12
Mutone 2004 [39] 407 Retrospective 288 (71) 120 (42) 0.75
Powers 2004 [42] 32 Retrospective Unknown 20 (63) Unknown
Broens-Oostveen 2004 [23] 192 Retrospective Unknown 107 (52) 64
Bai 2005 [20] 104 Retrospective Unknown 20 (19) Unknown
Hanson 2005 [30] 1,216 Retrospective 1,043 (86) 299 (29) 3
Fernando 2006 [27] 203 Prospective 203 (100) 106 (52) 4
Barber 2006 [21] 42 Prospective cross-over 42 (100) 0 (0) 3
Maito 2006 [37] 120 Retrospective 103 (86) 11 (11) 6
Cundiff 2007 [6] 134 Randomised cross-over 123 (92) 49 (40) 3
Komesu 2007 [34] 64 Prospective cohort study Unknown 28 (44) 12
Jones 2008 [32] 90 Prospective cohort study Unknown 48 (53) 3
Nager 2009 [40] 255 Randomised controlled trial 235 (92) No follow-up No follow-up
Kuhn 2009 [35] 73 Prospective cohort study Unknown 40 (55) 3
Sarma 2009 [43] 273 Retrospective 167 (61) 144 (86) 84
Friedman 2010 [28] 150 Retrospective Unknown 35 (23) 12
Patel 2010 [41] 75 Prospective cohort study 70 (93) 21 (30) 3
Abdool 2010 [19] 359 Prospective 359 (100) 116 (32) 12
aInitially fitting
bDropout at follow-up
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There may be a decrease in the size of the genital hiatus
with continued pessary use. This decrease is detected even
after 2 weeks of continuous pessary wearing [32]. There
may also be an improvement in POP stage after 1 year of
pessary treatment [29]. Such improvements may have been
due to a transient effect of pessary use [29, 38]. Limitations
of these papers are the small sample sizes. Whether this
reduction in POP stage sustains at the long term and
whether it is clinically relevant need further research.
Management and follow-up
Evidence is lacking on the type of pessary that is
chosen, or who should be responsible for cleaning and
changing pessaries and how often this should be
performed [14, 30]. Ideally, the physician can teach a
patient how to remove and replace the pessary herself.
This increases patients’ autonomy, allowing her to use it
and clean it when needed [5, 18]. In such a setting,
follow-up could be on an annual basis [18]. Patients who
are not willing or able to manage pessary care themselves
require more frequent doctors (or nurse practitioner)
visits. There is a lack of evidence on whether a pessary
should be used in combination with hormone replacement
therapy or pelvic floor exercises [3]. If HRT is prescribed,
local HRT seems to be more beneficial in reducing side
effects than systemic HRT or a combination of both [30].
HRT is particularly used to prevent vaginal irritation and
ulceration due to pressure oft h ep e s s a r yi na no l d e ra n d
atrophic vagina [17]. There is some evidence that local
HRT plays a significant role in the initial success of
fitting [30].
Complications and discomfort
The most common side effects of pessary use are a foul
smell, vaginal discharge, bleeding, pain and constipation
[43]. A recent study reported that 56% of women wearing
a pessary reported one of these side effects [43].
Changing a pessary at frequent intervals could prevent
this vaginal irritation. Therefore, it is helpful if the patient
is willing and able to remove, clean and replace the
pessary herself [18].
Rarely, pessaries cause major urinary, rectal and genital
complications such as fistula, faecal impaction, hydro-
nephrosis and urosepsis [1]. These rare complications are
almost exclusively related to a long period of use and
negligence of care. With regular follow-up, the majority of
pessary complications can be avoided and kept to a
minimum [9].
Conclusion
Pessary treatment is widely used for the treatment of
pelvic organ prolapse. It can be considered a patient-
friendly, minimally invasive treatment and appears to be
safe. Most studies reported successful fitting trial over
85%. Risk factors responsible for unsuccessful pessary
fitting are short vaginal length, a large genital hiatus,
prior history of hysterectomy and prior surgical repairs of
POP. The compartment and stage of POP have not been
reported to have any influence on successful pessary
fitting. Fifty percent to 80% of women who were initially
successfully fitted continued to use pessary at 1 year.
Continuation rates at greater than 5 years range from
14% to 48%. Consistent in most reports though are the
improvements in both bulge and irritative bladder
symptoms and the high satisfaction rates.
Sexual activity appears not to be a contraindication for
pessary treatment; on the contrary, it seems to have a
positive effect on sexual functioning. In comparison with
POP surgery, 1-year outcomes in terms of prolapse
symptoms, sexual functioning and quality of life seem
similar with pessary use.
Discussion
The aim of this review was to set up a systematic review on
articles that address health-related quality of life in pessary
treatment of pelvic organ prolapse. The limitation of this
review is the limited availability of published studies on
that issue. Another limitation is that in most published
papers, follow-up periods were short, usually less than
12 months. Long-term outcomes on the other hand were
inconsistent.
The use of validated urogynaecological questionnaires in
pessary treatment is still limited. In POP surgery, the use of
these validated tools is well established. The few papers in
which urogynaecological questionnaires were used do
suggest improvements in health-related quality of life
following pessary treatment. Comparison with other pro-
lapse therapies is rare and, if so, not yet assessed in a
randomised controlled trial.
More research is indicated, and it is our opinion that a
randomised controlled trial comparing pessary use with
surgical treatments of POP should be undertaken to
determine its therapeutic position in the management of
pelvic organ prolapse. Outcome measures of such a trial
642 Int Urogynecol J (2011) 22:637–644should be the change in urogenital bother and quality of
life scores.
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